Y0000001
Detomidine hydrochloride
European Pharmacopoeia (EP) Reference Standard
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Empirical Formula (Hill Notation):
C12H14N2 · HCl
CAS Number:
Molecular Weight:
222.71
UNSPSC Code:
41116107
NACRES:
NA.24
grade
pharmaceutical primary standard
API family
dexmedetomidine, medetomidine
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
InChI
1S/C12H14N2.ClH/c1-9-4-3-5-11(10(9)2)6-12-7-13-8-14-12;/h3-5,7-8H,6H2,1-2H3,(H,13,14);1H
InChI key
OIWRDXKNDCJZSM-UHFFFAOYSA-N
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Detomidine hydrochloride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
related product
Product No.
Description
Pricing
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
Sorry, we don't have COAs for this product available online at this time.
If you need assistance, please contact Customer Support.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Heather K Dimaio Knych et al.
American journal of veterinary research, 72(10), 1378-1385 (2011-10-04)
To characterize pharmacokinetics and pharmacodynamics of detomidine gel administered sublingually in accordance with label instructions to establish appropriate withdrawal guidelines for horses before competition. 12 adult racehorses. Horses received a single sublingual administration of 0.04 mg of detomidine/kg. Blood samples
Jiske J L'Ami et al.
Veterinary journal (London, England : 1997), 196(2), 253-259 (2012-10-16)
A single dose of 40 μg/kg bodyweight (BW) of oromucosal detomidine gel was administered sublingually to 10 healthy Dutch Warmblood mares aged 7 ± 4 years (mean ± SD) and BW 580 ± 69 kg. Blood and urine samples were
Heather K DiMaio Knych et al.
Veterinary anaesthesia and analgesia, 39(6), 574-583 (2012-10-06)
To describe selected pharmacodynamic effects of detomidine and yohimbine when administered alone and in sequence. Randomized crossover design. Nine healthy adult horses aged 9 ± 4 years and weighing 561 ± 56 kg. Three dose regimens were employed in the
F Javier López-Sanromán et al.
American journal of veterinary research, 74(6), 828-834 (2013-05-31)
To evaluate the duration of effects on movement patterns of horses after sedation with equipotent doses of xylazine hydrochloride, detomidine hydrochloride, or romifidine hydrochloride and determine whether accelerometry can be used to quantify differences among drug treatments. 6 healthy horses.
Assessment of the sedative effects of buprenorphine administered with 10 μg/kg detomidine in horses.
E J Love et al.
The Veterinary record, 168(14), 379-379 (2011-04-19)
The aim of this randomised, observer-blinded, crossover study was to compare the effects of six treatments, administered intravenously to six horses: saline and saline (S/S); detomidine and saline (D/S); detomidine and 5 µg/kg buprenorphine (D/B5); detomidine and 7.5 µg/kg buprenorphine
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service